Biomarkers Market worth $112.10 billion by 2031 | MarketsandMarkets™

MarketsandMarkets projects the global biomarkers market will grow from ~$67.95B in 2026 to ~$112.10B by 2031 (10.5% CAGR). The report highlights a 73.4% 2025 share for consumables, a 48.5% 2025 share for safety biomarkers, and faster Asia Pacific growth at a 12.4% CAGR. Growth is attributed to increased biomarker use in drug discovery/clinical trials, expansion of liquid biopsy and minimally invasive testing, and AI-enabled multi-omics analysis.

Analysis

This is more useful as a channel check than as a tradable catalyst: the growth is real, but the value capture is uneven. The best setup is for recurring consumables and service-heavy vendors with high installed-base pull-through, while pure instrument names risk seeing demand diluted by pricing pressure and slower replacement cycles. That argues for relative winners like TMO, QGEN, RVTY, and CRL over more capital-intensive, slower-turning peers; the economic moat is not the TAM, it is who controls workflow lock-in and validated assay content.

Second-order effects matter more than the headline size: biomarker adoption shifts spend from discretionary discovery tools into regulated, protocolized testing embedded in pharma trials and clinical labs. That should help CROs and reference-lab adjacent players over 6-18 months as more trials require companion-diagnostic style stratification, but it also raises the bar for smaller diagnostic vendors that lack reimbursement, regulatory, or data-network scale. AI-enabled analysis is supportive for throughput, yet it can compress differentiation unless paired with proprietary datasets or FDA-cleared workflows.

The contrarian read is that consensus is likely overcalling a straight-line benefit to the whole tools basket. If macro funding stays soft, the fastest-growing end markets may still under-earn versus this TAM because biopharma will prioritize higher-ROI, late-stage and safety-oriented biomarkers rather than broad exploratory spend. The main falsifier is a slowdown in pharma CapEx/biomarker-associated trial starts over the next 1-2 quarters, or evidence that pricing compression offsets volume gains in consumables.

Key Decisions for Investors

• Overweight TMO and QGEN versus the broader life-science tools basket on a 3-6 month view; best risk/reward is in recurring consumables and assay workflow leverage, not headline TAM beta.
• Long RVTY / short a lower-quality instruments basket or smaller-cap diagnostics exposure for 1-3 months; thesis is that biomarker growth accrues to validated workflow owners rather than undifferentiated platform vendors.
• Add CRL on weakness as a 6-12 month beneficiary of biomarker-heavy trial design and outsourced study complexity; monitor utilization and margin expansion as the key falsifier.
• Avoid chasing the news as a one-day event trade: the report is directional, but not a near-term revenue revision. Use it as a watchlist trigger for Q2/Q3 guidance from TMO, QGEN, RVTY, and CRL.
• If one wants a hedge, short any sharp multiple expansion in smaller diagnostics names that lack reimbursement or proprietary data moat; the market may be overestimating how much of this TAM is monetizable.